
GenEdit Inc., a biotech firm in California, innovates CRISPR-based therapeutic delivery systems.
GenEdit Inc., founded in California, is a biotechnology company dedicated to developing innovative delivery systems for CRISPR-based therapeutics. Their core mission is to revolutionize genetic medicine by creating precise and efficient delivery mechanisms for gene editing technologies. GenEdit's vision is to unlock the full potential of genetic therapies to treat a wide range of diseases. The company focuses on providing comprehensive solutions that enhance the efficacy and safety of CRISPR-based treatments, targeting both rare and common genetic disorders.
Notable figures associated with GenEdit include experts in biotechnology and genetic research, though specific names are not provided. The company has attracted significant interest from investors in the biotech sector, reflecting confidence in its cutting-edge approach. Key achievements include the development of proprietary delivery platforms that have shown promise in preclinical studies. GenEdit's impact lies in its potential to transform the landscape of genetic medicine, offering hope for more effective treatments and cures for genetic diseases.

Editas Medicine

Synthego
synthego.com

Mammoth Biosciences

Intellia Therapeutics
intelliatx.com

Amber Bio
amber.bio

Acrigen Biosciences
acrigen.com

eGenesis
egenesisbio.com

Metagenomi
metagenomi.co

Scribe Therapeutics
scribetx.com

Genetica
genetica.asia

GeneTether
genetether.com

CellFE

Caribou Biosciences
cariboubio.com

Nvelop Therapeutics

Emendo Biotherapeutics
emendobio.com
Companies similar to GenEdit include Editas Medicine, Synthego, Mammoth Biosciences and Intellia Therapeutics.
GenEdit was founded in 2016.
GenEdit's headquarters is located in South San Francisco, CA, US.
GenEdit's most recent funding round was for $24M (USD) in January 2024.
As of Jan 23, 2024, GenEdit has raised a total of $67.7M (USD).
GenEdit has 47 employees as of Feb 4, 2024.